Heart Iron in Thalassemia Major Patients
Author Information
Author(s): Pepe Alessia, Meloni Antonella, Rossi Giuseppe, Dell'Amico Maria Chiara, Prossomariti Luciano, D'Ascola Domenico G, Filosa Aldo, Pepe Pasquale, Positano Vincenzo, Ascioti Claudio, Capra Marcello, Lombardi Massimo
Primary Institution: G. Monasterio Foundation and Institute of Clinical Physiology, CNR, Pisa, Italy
Hypothesis
Is there a difference in cardiac iron changes in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus monotherapy?
Conclusion
Sequential DFP-DFO treatment did not show significant differences in cardiac iron compared to DFO, while DFP monotherapy was more effective.
Supporting Evidence
- The study involved 739 thalassemia major patients, with 253 completing MR follow-up.
- Patients were treated with either sequential DFP-DFO or monotherapy with DFP or DFO.
- No significant differences in compliance levels were found among treatment groups.
- Patients without significant myocardial iron overload showed no differences in maintaining MIO status.
- Only DFP and DFO showed significant improvement in myocardial iron concentrations.
- The improvement in global heart T2* was significantly lower in the DFP-DFO group compared to DFP.
Takeaway
This study looked at how different treatments affect heart iron in patients with thalassemia. It found that one treatment worked better than another for improving heart health.
Methodology
Patients underwent MR follow-up studies to measure myocardial iron concentrations using T2* multislice multiecho technique.
Participant Demographics
Thalassemia major patients, with 739 enrolled and 253 completing the study.
Statistical Information
P-Value
0.001, 0.003, 0.031, 0.0001, 0.007, 0.014, 0.63
Statistical Significance
p=0.007
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website